Abstract: UDP-glucuronosyltransferases 1A8 (UGT1A8) is an important enzyme responsible for glucuronidation of numerous xenobiotic/drugs. The objective of this study is to establish a substrate selectivity model through pharmacophore approach. 2. Thirty-six substrates of UGT1A8 collated from the literature were divided into training (n = 24) and test sets (n = 12). The Discovery Studio 2.5 (DS) software was utilized to establish the pharmacophore model. The HypoGen algorithm that was available in 3D QSAR Pharmacophore Generation protocol was applied to construct pharmacophore hypotheses. The established pharmacophore model consisted of two hydrogenbonding acceptors and one ring aromatic. The best pharmacophore model (hypothesis 1) was statistically significant with high value of correlation coefficient and low value of difference between the null cost and the total cost. Besides, the predicted catalysis activities were within one log residual of experimental value for substrates in the test set. In summary, a pharmacophore model for UGT1A8 was successfully constructed for the first time in this study. The established model contributed to an improved understanding of the UGT1A8's substrate selectivity. Besides, this model would be an efficient tool for high-throughput prediction of UGT1A8 metabolism.
Introduction
Glucuronidation is a major pathway for xenobiotic/drugs metabolism and excretion in humans and other mammalian species [1] . This reaction occurs via transfer of a glucuronic acid from cofactor UDP-glucuronic acid (UDPGA) to a compound that usually contains a hydroxyl, carboxyl or nitrogen group [2] . Glucuronidation can enhance hydrophilicity of a compound, resulting in enhanced excretion rate of xenobiotic/drugs from the body [1] . In most instances, the glucuronidated metabolites are inactive [3] . However, glucuronidation can generate pharmacologic or toxicologic activity in some instances [3] . For example, morphine-6-glucuronide is a more potent opioid agonist than morphine [4] . On the basis of amino acid sequence identity, UDP-glucuronosyltransferases (UGTs), which specifically catalyze the reaction of glucuronidation, are divided into four families: UGT1, UGT2, UGT3 and UGT8 [5] . The most important drug-conjugating UGTs are UGT1A and UGT2B family [1] . Of note, UGT 1A8 expressed in the small intestine and colon plays a key role in clearance of many drugs such as isoflavones, gingerols and curcumin analogs [6] [7] [8] .
Pharmacophore model is a collectivity of electronic and steric features which is essential for the optimal supramolecular interaction with a specific biologic target to initiate (or block) its biologic response [9] . There two kind of pharmacophore model, namely, ligand-based and structure-based pharmacophore model [10] . Ligand-based pharmacophore model is constructed by overlying a group of active compounds and extracting common chemical features which are necessary for their bioactivity. On the contrary, structure-based pharmacophore model can only be utilized when a three dimensional (3D) structure of a biological target is available. Besides, pharmacophore techniques have been widely used as a 3D-QSAR (3D-quantitative structure-activity relationship) method to predict ADME (Absorption, Distribution, Metabolism and Excretion) properties in recent years [11] .
The substrate selectivity of many UGTs (e.g. UGT1A1, UGT1A3, UGT1A7) and cytochrome P450 enzymes involved in the oxidation of much xenobiotic/drugs (e.g. CYP 1A2, 2B6, 2C9 and 3A4) have been well understood and predicted using pharmacophore approach [11, 12] .
High rate of drug attrition is usually caused by the poor properties of ADME [13] . Hence, it is necessary to deal with ADME issues earlier in the drug discovery cycle using effective computational tools. However, QSAR models are still unavailable for UGT1A8 enzyme. Therefore, a predictive QSAR model for UGT1A8 is of great value in an attempt to predict the glucuronidation of drug candidates. In this study, we have evaluated the potential of pharmacophore approach in quantifying the substrate selectivity of UGT1A8. Discovery Studio 2.5 was used to build the pharmacophore model. Thirty-six UGT1A8's substrates collated from the literature were divided into two sets, namely, training set (n = 24) and test set (n = 12). The predictive power of the established pharmacophore model was validated via cost analysis, Fisher's randomization test and test set verification. We demonstrated for the first time that the pharmacophore model possessed predictive capability was successfully constructed for UGT1A8, contributing an improved understanding of the UGT1A8's substrate selectivity and a more comprehensive prediction of UGT-mediated metabolism.
Results

Construction of the pharmacophore model
Twenty-four UGT1A8 substrates included in the training set ( Figure 1A ) were used to construct the pharmacophore model. The activities (CLint) for these compounds spanned four orders of magnitude ( Figure 1 ). Ten pharmacophore hypotheses were generated by the HypoGen algorithm. It was interesting to find that all hypotheses included two hydrogen-bond acceptors (HBA) and one ring aromatic (RA), suggesting that these chemical features play an important role in the UGT1A8 activity (Table 1) . On the basic of cost and correlation analysis, hypothesis 1 was regarded as the best model (Table 1 ). The structural features and geometry of hypothesis 1 were presented in Figure 2A . The ring aromatic was 5.2 Å away from one hydrogen-bond acceptor and 4.5 Å away from the other one. The most active substrate genistein (CLint = 1810 l/mg/min) was well mapped to the model features ( Figure 2B ). By contrary, the least active substrate morphine (CLint = 0.71 l/mg/min) was poorly fitted to all features ( Figure 2C ). This suggested that the established pharmacophore model could distinguish good UGT1A8 substrates from poor ones. b Correlation coefficient (R) between the predicted activity and the experimental activity of the training set.
c Abbreviations used: RMS, root mean square deviation; HBA, hydrogen-bond acceptor; RA, ring aromatic.
Validation of the pharmacophore model
Firstly, cost analysis was applied to model validation. The cost values for all hypotheses were listed at Table 1 . The total cost (113.79) was close to the fixed cost (104.65) for hypothesis 1. Besides, the difference between the null cost and the total cost was 43.73, indicating that there was a high chance (75%-90%) that the model represented a good correlation of the information. This was agreed well with the fact that this model showed an excellent correlation coefficient (r = 0.8334) between predicted and experimental activities for substrates in training set ( Figure 3) . Furthermore, the configuration cost (10.431) was not greater than 17, suggesting that a standard HypoGen algorithm was performed [14] .
The pharmacophore model was then assessed by cross-validation using Fischer's randomization method. Nineteen hypotheses were generated randomly ( Figure 4) . Clearly, all nineteen generated hypotheses after randomization showed higher total cost value compared to the original hypothesis ( Figure 4 ). This result demonstrated that the original hypothesis was not generated randomly.
Finally, the correlation coefficient between predicted and experimental values for the test set substrates ( Figure 1B ) was used to evaluate reliability of the hypothesis 1. Predicted and experimental values for the test set were listed at Table 2 . A good correlation coefficient (r 2 = 0.823) was obtained for the model. Besides, the predicted CLint values was close to the experimental values for all substrates, deviating by no more than one log unit ( Figure 5 ).In fact, predicted value within one log residual of experimental value was considered satisfactory in drug metabolism field. [15, 16] . 
Discussion
In this study, a 3D QSAR model for UGT 1A8 was successfully established by pharmacophore approach for the first time. The pharmacophore model consisted of two HBA and one RA chemical features, demonstrating that HBA and RA served an important role in the catalyzing capability of UGT 1A8 (Figure 2 ). Therefore, this study highlighted an overlay of chemical characteristics related to UGT1A8 substrates. Furthermore, this model possessed strong capacity to predict substrate activity for UGT 1A8 (Figure 4) . Accordingly, the established model would be an efficient tool for high-throughput prediction of UGT1A8 metabolism. UGT1A8 was a major UGT enzyme contributing to drug metabolism in the gastrointestinal tract [3] . However, the computational models were still unavailable for UGT 1A8. Hence, construction of the pharmacophore model for UGT1A8 in this study would be helpful for the prediction of UGT-mediated metabolism in the gastrointestinal tract.
Many drug attritions caused by undesirable ADME properties have led to the need to identify ADME problems in the drug discovery process as early as possible [17] . In fact, there two kind approaches (i.e. in silico and in vitro) could be utilized to optimize the selection of the most suitable drug candidates for development [16] . In silico approaches were effective to deal with ADME problems still earlier in the drug discovery process and helpful to select better drug candidates from many compounds to move forward [18] . On the contrary, in vitro approaches for ADME issues were time and economy consuming process. Of note, the pharmacophore technique was a powerful computational tool for ADME properties' prediction, which has successfully quantified substrate selectivity for various CYP and UGT enzymes [11] .
Because the full crystal structure for UGT 1A8 was unavailable, the ligand-based pharmacophore method was used to build the quantitative pharmacophore model. In order to ensure significative performing of the HypoGen algorithm, twenty-four structurally diverse substrates of UGT 1A8 covering a range of more than four log units were selected for model building (Figure 1 ). Therefore, it was reasonable that ten pharmacophore models were statistically significant with high values of correlation coefficients and low values of total cost (Table 1) . Besides, the hypothesis 1 (the best pharmacophore model) correctly predicted the activities of substrates in the test set (deviations of less than one log unit), suggestive of a good external predicted ability of the model ( Figure 5 ).
The pharmacophore model indicated that hydrogen-bonding acceptor played a significant role for the molecules glucuronidation by UGT1A8, consisting with the results of pharmacophore analysis for UGT1A3 and UGT2B7 [19, 20] . Hydrogen-bond acceptor was regarded as a hydrophilic group.
Accordingly, this result was also supported the fact that hydrophilic region was an important contributor to substrate catalysis. Besides, pharmacophore analysis was firstly demonstrated that ring aromatic was an essential determinant for glucuronidation activity by UGT enzyme. Ring aromatic provided strong hydrophobic properties in molecules. Noteworthily, hydrophobicity has been found to be an important factor for the binding of substrates to UGT enzymes such as UGT1A1, UGT1A4 and UGT1A10 [12] . Because catalysis efficiency was closely related to substrate binding to the enzyme, it was reasonable to find that ring aromatic was important for molecules' glucuronidation by UGT 1A8.
In conclusion, a quantitative model for UGT 1A8 was firstly constructed using pharmacophore approach in the present study. The pharmacophore model was composed of two hydrogen-bonding acceptors and one ring aromatic. We also found that the best pharmacophore model (hypothesis 1)
was statistically significant with high values of correlation coefficients and low values of difference between the null cost and the total cost. Besides, the established model was able to accurately predicted catalysis activity within one log residual of laboratorial value for substrates in the test set, highlighting the predictability of the model. Application of the established model to predict UGT1A8 metabolism, hence, is fully expected in drug development problems. Our model could also contribute to an improved understanding of the substrate selectivity of UGT1A8.
Materials and Methods
Data preparatio
For the pharmacophore modeling study, a series of thirty-six diverse substrates of UGT1A8 was collated from the literature (Figure 1 ). The intrinsic clearance value (CLint) that derived from kinetic determination was regarded as glucuronidation activity. The CLint values and references for all substrates were listed in the supplementary material. Based on the principles of wide coverage of the activity (four orders of magnitude) and chemical structural diversity, all substrates were randomly divided into training (n = 24) and test sets (n = 12). The training set was applied to construct the pharmacophore model, while the test set was served to evaluate the external predictive ability of the established model. The three dimensional (3D) structures of all compounds were prepared by Discovery Studio 2.5 (DS) (Accelrys, US). Gasteiger-Marsili method was used to determine partial atomic charges.
Pharmacophore model generation
The generation of pharmacophore model was performed using Discover Studio 2. 
Pharmacophore model validation
In this study, the generated model was validated by three methods: cost analysis, Fisher's randomization test and the test set prediction. First, the quality of a pharmacophore model can be assessed in terms of null cost, total cost and fixed cost. As a fine pharmacophore model, the difference between the null cost and the total cost values should be small. Besides, the fixed cost should be close to the total cost. Then, the Fisher's randomization test was applied to assessed the statistical relevance to the model. In this test, the activity values of substrates in the training set were randomly reassigned before hypotheses generation. The confidence level was set to 95%, where 19 random hypotheses were yielded. Finally, the test set prediction was used as an external model validation method. The substrates in the test were mapped to the best pharmacophore model to obtain their predicted CLint values using the Ligand Pharmacophore Mapping protocol.
Supplementary Materials: The following are available online. The references of UGT1A8 substrates are available as supporting information.
